CLYM Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 32.88%, SMA50 51.57%, SMA200 192.14%). The stock’s 14-day RSI is 74.9 (overbought), while the ATR of 0.53 points to higher daily volatility. The stock remains currently trading near 52-week highs, trading 4.09% below its high and over 602.86% above its low. Average 10-day trading volume of 1.96 million shares is slightly above the 3-month average of 1.43 million, indicating heightened recent market interest.

Climb Bio, Inc. has 57.44 million shares outstanding. The public float is 41.60 million shares, elevated short interest at 17.93% of float. This equals 7.30 million shares. The short ratio is 6.03 days. Institutional investors hold 65.02% of the float. Insiders own 0.37%. RA CAPITAL MANAGEMENT, L.P. holds 3.40 million shares, Thomas Stephen Basil has 467.97 thousand shares and Brennan Aoife has 87.73 thousand shares. Over the past six months, insider transactions show net selling. They sold 130.90 thousand shares across 2 transactions.

Climb Bio, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.52. This means the shares are trading above this model’s fair value.

Climb Bio, Inc. generated EPS of -$0.75 over the past year. Five-year average earnings growth is -40.44%. Wall Street analysts project EPS growth of 10.82% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 13 Strong Buy ratings, 17 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $35.00 to $8.00. The high target offers 200.17% upside. The low target suggests -31.39% downside. The mean target is $18.83. This offers 61.49% upside. Climb Bio, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by -14.0%. The prior quarter beat by -23.08%. Over the last six quarters, Apple has recorded several small beats. These include 106.67% in May 14, 2025.

Climb Bio, Inc. (NASDAQ:CLYM) closed at $11.66 USD, losing -$0.23 (-1.93%) from the previous close of $11.89. The stock is currently mid-range between its 52-week high and low $1.54 and $18.33. With a market capitalization of about $667.69 million, Climb Bio, Inc. is classified as a small-cap and shows lower-than-market volatility (beta ~0.07). Key stats such as the average daily volume over the past year has been around 1.43 million shares, in line with its 52-week average. Headquartered in Wellesley Hills, MA, Climb Bio, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Aoife Brennan BCh MMSc, the company employs approximately 28 people and listed since August 10, 2021. Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses.

Climb Bio, Inc. trades at a P/E ratio of -14.05, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 3.71 trading at moderately above to book value. The P/FCF stands at -12.58, also below market averages.

Our AI price prediction model suggests that Climb Bio, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -2.66%, with price expected at $11.35 by October 09, 2026, within a range of $9.82 to $12.83 3-Month Outlook: Projected rise of 29.76%, reaching $15.13 by December 24, 2026, with a range of $14.92 to $15.29. 1-Year Outlook: Projected gain of 155.15%, with price at $29.75 by September 24, 2027, within a range of $29.85 to $30.24.

Climb Bio, Inc. (NASDAQ:CLYM) shares are flat 8.0% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Climb Bio, Inc. trading at a premium to the broader market with a P/E of -14.05. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $17.91, suggesting 53.6% upside. Our AI forecast model points to short-term weakness (-2.66% over two weeks), a medium-term rise (29.76% over three months), and a longer-term gain (155.15% over one year), with expected trading ranges indicating moderate volatility.